Skip to content

Diffusion tensor imaging in patients with Parkinson's disease and cognitive impairment and olfactory dysfunction

Diffusion tensor imaging in patients with Parkinson's disease and cognitive impairment and olfactory dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077691
Enrollment
Unknown
Registered
2023-11-16
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

experimental group:none
control group:none

Sponsors

The Second People's Hospital of Guiyang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: I. Inclusion criteria for the experimental group: Meet the clinical diagnosis criteria of Parkinson's disease established by the International Movement Disorders Society (MDS) in 2015. II. Inclusion criteria for the control group: 1. Have no brain injury or structural lesion; 2. Have no nasal or sinus disease or surgery history; 3. Voluntarily participate in the study.

Exclusion criteria

Exclusion criteria: I. Exclusion criteria for the experimental group: 1. Exclusion criteria: (1) Other neurological diseases with possible olfactory dysfunction, such as Alzheimer's disease, multiple sclerosis, schizophrenia, etc.; (2) History of severe brain injury or intracranial surgery; (3) History of nasal or sinus disease or surgery; (4) Pregnant or breastfeeding women; (5) Recent (within 2 weeks) history of upper respiratory infection; (6) Pregnant or breastfeeding women; (7) Individuals who have poor compliance and are unable to complete olfactory and cognitive tests and magnetic resonance imaging examinations due to poor compliance. II. Exclusion criteria for the control group: (1) Individuals with olfactory test and cognitive function test indicating impairment; (2) History of neuropsychiatric disorders and related drug use; (3) Individuals with severe internal medicine diseases such as heart, liver, and kidney disease; (4) Individuals who are unable to complete cognitive function tests, olfactory function tests, and magnetic resonance imaging examinations due to poor compliance.

Design outcomes

Primary

MeasureTime frame
FA,fractional anisotropy;MD,mean diffusivity ;

Secondary

MeasureTime frame
AD,axial diffusivity;RD,radial diffusivity;

Countries

China

Contacts

Public ContactTian Bin

The Second People's Hospital of Guiyang

mrtian@sr.gxmu.edu.cn+86 150 8596 5143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026